DENVER, CO – CB Scientific, Inc. (OTC PINK: CBSC), a designer, developer and manufacturer of Life Science Analytical Tools and Devices, laboratory services and personal analytical kits and devices, announces today that it has begun a trial evaluation of its “Test4THC” single-use test kit with a large government agency.
CB Scientific developed a mobile marijuana detection kit for use as a determinant of probable cause to test any products in possession including oils, concentrates, and edibles for the presence of THC. The company hopes to sign an agreement with the agency by the end of second quarter 2016.
“Our TEST4THC product line was inspired by growing demand for a quick and simple THC detection tool. Our Generation 3 closed-system, single use kit met the need for potential use by law enforcement, military, schools or private companies operating within the law to test products used by impaired drivers, government personnel, children or employees,” said Sam Talari, CEO of CB Scientific.
The kits have been improved multiple times and have now been simplified into an all-in-one Gen 3 test kit, providing a sealed test with the benefit of having a closed system and very simple procedure which can be done in less than a minute with the confirmed results occurring in less than 10.
With over two years in personal analytics development process, our products have allowed CB Scientific to gain the attention of government and private organizations (police departments, military, schools, and concerned parents) that could benefit from having a fast, simple, and accurate THC detection kit. The Company is currently making improvements to packaging to make the kits available worldwide.
CB Scientific will also be supplying testing and analytical equipment for FutureLand Corp (OTC PINK: FUTL) new medical/recreational facility being purchased in Oregon. The analytical tools will enable FutureLand to manage quality and potency of its productions.
About CB Scientific , Inc.
CB Scientific (www.cbscientific.com), based in Denver, Colorado, through its subsidiaries, designs, develops and manufactures Life Science Analytical Tools and Devices, laboratory services, personal analytical kits and devises and CBD hemp oil and nutraceutical formulations for growers, care takers, dispensaries and companies worldwide. CB Scientific is continuing to develop new technologies specifically for cannabis (hemp) analytics. CB Scientific believes every product sold to patients as “Medical Quality” should be inspected for health benefits, safety, consistency, purity, potency and packaged properly for distribution. CB Scientific has worked with many of the cannabis industry leaders in the country and have also been featured in cannabis industry publications including High Times Magazine, Culture and many trade publications, on-air interviews and panel discussions across the United States. CB Scientific’s focus has been the education and safety of consumers combined with innovation to put power into the hands of the patients.
To request further information about CB Scientific, please email us at email@example.com, log onto our website at http://www.cbscientific.com or visit us on Twitter @cbscientific and Facebook at cbscientificinc.
About FutureWorld Corp.
FutureWorld (OTC PINK: FWDG), a Delaware corporation, is a leading provider of advanced technologies and solutions to the global cannabis industry. FutureWorld, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of cannabis related products and services, such as industrial Hemp. FutureWorld, through its subsidiaries, provides personal and professional THC and CBD test kits, pharmaceutical grade CBD oil solutions, SafeVape vaporizers, smart sensor technology, communication network, surveillance security, data analysis for smart cultivation and consultation for the industrial hemp and legal medicinal cannabis. Our wireless agricultural smart sensor networks offer precision to the agriculture, irrigation systems, and greenhouses for the global cannabis and hemp industry. FutureWorld and its subsidiaries do not grow, distribute or sell marijuana. As the only Cannabis Technology Accelerator, FutureWorld will incubate and fund leading technologies, products, and services for Cannabis industry (Industrial Hemp) for foreseeable future; bringing value to its core and its shareholders.
To request further information about FutureWorld, please email us at firstname.lastname@example.org, log onto our website at http://www.futureworldcorp.com or visit us at our Facebook page facebook.com/futureworldcorp or on Twitter @futureworldinc.
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.